Shares are down $11.78, or 32%, to $24.92 after trading resumed following an earlier halt.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SMMT:
- Summit Therapeutics trading resumes
- Summit Therapeutics to resume trading at 3:20 pm ET
- Summit Therapeutics says new ivonescimab data clinically meaningful
- Wells says Summit, Akeso data ‘not the bull case,’ but not ‘bear case either’
- Akeso reports ivonescimab receives NMPA approval to treat NSCLC in China